• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Frazier Lifesciences Acquisition Corporation

    12/2/22 4:30:53 PM ET
    $FLAC
    Business Services
    Finance
    Get the next $FLAC alert in real time by email
    15-12G 1 d325794d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-39765

     

     

    Frazier Lifesciences Acquisition Corporation

    (Exact name of registrant as specified in its charter)

     

     

    Two Union Square

    601 Union St., Suite 3200

    Seattle, Washington 98101

    (206) 621-7200

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Units, each consisting of one Class A Ordinary Share, and one-third of one Warrant to acquire one Class A Ordinary Share

    Class A Ordinary Shares, par value $0.0001 per share

    Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: one (1).

    Pursuant to the requirements of the Securities Exchange Act of 1934, Frazier Lifesciences Acquisition Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: December 2, 2022     FRAZIER LIFESCIENCES ACQUISITION CORPORATION
        By:   /s/ Louise Kooij
        Name:   Louise Kooij
        Title:   Treasurer

     

     

     

    Get the next $FLAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance
    • Frazier Healthcare Partners Announces Several Promotions on Life Sciences Team

      Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired

      10/28/21 8:00:00 AM ET
      $FLAC
      $ISEE
      $KRYS
      $RCKT
      Business Services
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      2/15/23 10:14:02 AM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      12/1/22 4:51:17 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form SC 13D/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)

      SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/25/22 1:43:14 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Viking Global Investors Lp

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/25/22 1:35:02 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Topper David Joseph

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:31:11 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 4 filed by Bigham Michael

      4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)

      11/23/22 4:27:56 PM ET
      $FLAC
      Business Services
      Finance

    $FLAC
    Leadership Updates

    Live Leadership Updates

    See more
    • Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

      FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he

      9/26/22 8:00:00 AM ET
      $ALPN
      $ANAB
      $FLAC
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Finance

    $FLAC
    SEC Filings

    See more
    • SEC Form 15-12G filed by Frazier Lifesciences Acquisition Corporation

      15-12G - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      12/2/22 4:30:53 PM ET
      $FLAC
      Business Services
      Finance
    • Frazier Lifesciences Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)

      11/23/22 4:36:01 PM ET
      $FLAC
      Business Services
      Finance
    • SEC Form 25-NSE filed by Frazier Lifesciences Acquisition Corporation

      25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)

      11/22/22 4:17:19 PM ET
      $FLAC
      Business Services
      Finance